DCTH
HEALTHCAREDelcath Systems Inc
AI Insight
What's Moving DCTH Today?
No stock-specific AI insight has been generated for DCTH yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.12$14.18
$12.50
Fundamentals
Market Cap$397M
P/E Ratio1,151.0
EPS$0.01
Dividend Yield—
Dividend / Share—
ROE0.6%
Profit Margin0.6%
Debt / Equity—
Trading
Volume78K
Avg Volume (10D)—
Shares Outstanding34.5M
DCTH News
23 articles- Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress AbstractsYahoo Finance·May 26, 2026
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 15, 2026
- Delcath Shareholders Approve Expanded Equity Plan and GovernanceTipRanks·May 14, 2026
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceYahoo Finance·May 12, 2026
- Delcath Systems Q1 2026: -$0.03 EPS Tops Estimates — Deep DiveAlphaStreet·May 11, 2026
- Delcath (DCTH) Q1 2026 Earnings TranscriptMotley Fool·May 8, 2026
- Delcath Systems Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Delcath Systems Reports First Quarter 2026 Results and Business HighlightsYahoo Finance·May 7, 2026
- A liver-targeted breast cancer procedure drew new data at ESMOStock Titan·May 7, 2026
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026Yahoo Finance·May 7, 2026
- How The Delcath Systems (DCTH) Story Is Shifting With Hepzato Milestones And 2026 GuidanceYahoo Finance·May 1, 2026
- Delcath Systems to Host First Quarter 2026 Earnings CallYahoo Finance·Apr 23, 2026
- Implied Volatility Surging for Delcath Systems Stock OptionsYahoo Finance·Apr 7, 2026
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal MelanomaYahoo Finance·Apr 6, 2026
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 MeetingYahoo Finance·Apr 1, 2026
- Delcath Systems publishes results from CHOPIN trial in The Lancet OncologyYahoo Finance·Mar 4, 2026
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet OncologyYahoo Finance·Mar 3, 2026
- Delcath Systems Inc (DCTH) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ...Yahoo Finance·Feb 26, 2026
- Delcath Systems Q4 Earnings Call HighlightsMarketbeat·Feb 26, 2026
- Delcath (DCTH) Q4 2025 Earnings Call TranscriptMotley Fool·Feb 26, 2026
- Delcath Systems, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 26, 2026
- Delcath Systems Reports Fourth Quarter and Full Year 2025 ResultsYahoo Finance·Feb 26, 2026
All 23 articles loaded
Price Data
Open$12.36
Previous Close$12.29
Day High$12.75
Day Low$12.36
52 Week High$14.18
52 Week Low$8.12
52-Week Range
$8.12$14.18
$12.50
Fundamentals
Market Cap$397M
P/E Ratio1,151.0
EPS$0.01
Dividend Yield—
Dividend / Share—
ROE0.6%
Profit Margin0.6%
Debt / Equity—
Trading
Volume78K
Avg Volume (10D)—
Shares Outstanding34.5M
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—